Measurements of Islet Function and Glucose Metabolism with the Dipeptidyl Peptidase 4 Inhibitor Vildagliptin in Patients with Type 2 Diabetes
Author(s) -
Koichiro Azuma,
Žofia Rádiková,
Juliet Mancino,
Frederico G. S. Toledo,
Ernestine Thomas,
Cyrous O. Kangani,
Chiara Dalla Man,
Claudio Cobelli,
Jens J. Holst,
Carolyn F. Deacon,
Yan-Ling He,
Monica LiguerosSaylan,
Denise Serra,
James E. Foley,
David E. Kelley
Publication year - 2007
Publication title -
the journal of clinical endocrinology and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.206
H-Index - 353
eISSN - 1945-7197
pISSN - 0021-972X
DOI - 10.1210/jc.2007-1369
Subject(s) - vildagliptin , islet , dipeptidyl peptidase 4 , type 2 diabetes , dipeptidyl peptidase , dipeptidyl peptidase 4 inhibitor , endocrinology , medicine , diabetes mellitus , function (biology) , chemistry , biochemistry , biology , enzyme , microbiology and biotechnology
Pharmacological inhibition with the dipeptidyl peptidase 4 (DPP-4) inhibitor vildagliptin prolongs the action of endogenously secreted incretin hormones leading to improved glycemic control in patients with type 2 diabetes mellitus (T2DM). We undertook a double-blinded, randomized-order, crossover study to examine the vildagliptin mechanisms of action on islet function and glucose utilization.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom